Journal of cardiac surgery
-
Amrinone and dobutamine compare favorably in the treatment of chronic congestive heart failure. There is increasing evidence that amrinone alone or in combination with a catecholamine may be used with considerable success in treating patients who are difficult to wean from cardiopulmonary bypass or who have a low cardiac output syndrome after coronary artery bypass grafting surgery. Amrinone increases intramyocardial cyclic adenosine monophosphate and exerts positive inotropic activity in addition to being a potent vasodilator. ⋯ When compared with dobutamine as primary treatment for depressed myocardial function in patients being weaned from cardiopulmonary bypass after coronary artery bypass grafting surgery, it was more effective in achieving primary treatment objectives. Patients given dobutamine had a higher incidence of myocardial infarction, ventricular fibrillation, supraventricular tachyarrhythmias, sinus tachycardia, and hypertension compared to those given amrinone. It is concluded that amrinone compares favorably with dobutamine and may even be superior when used as primary treatment for treating myocardial depression in patients having coronary artery surgery supported by cardiopulmonary bypass.
-
Traditionally, surgeons have attempted to minimize myocardial ischemic and reperfusion injury during cardiac procedures by optimizing cardioplegic solutions and modifying the conditions of reperfusion. New evidence suggests that in addition to these two strategies, surgeons may be able to induce myocardial resistance to ischemic injury, which permits immediate functional and metabolic recovery after cardiac operations. Although brief episodes of cardiac ischemia may be associated with mechanical and metabolic dysfunction ("stunning"), they have also been shown to protect against damage resulting from a subsequent prolonged ischemic episode. ⋯ Recent studies in surgical models of cardioplegic arrest and reperfusion have suggested that the preconditioned, arrested heart may have an increased tolerance to prolonged ischemia and improved functional recovery after reperfusion. The development of a pharmacological agent that induces the preconditioning effect may revolutionize cardioprotection for cardiac surgery. We will review the characteristics of preconditioning and data supporting the application of this natural protective capacity to reduce ischemic damage during cardiac procedures.